Research News and Research

RSS

USAID committed to early action on Sahel drought, drawing from lessons from Horn response

"A year after the worst drought in 60 years sent 13.3 million people in the Horn of Africa into crisis, we are now facing a rising threat of crisis in the Sahel -- an arid belt that stretches from Senegal through Niger and Burkina Faso to Chad," Nancy Lindborg, head of democracy, conflict, and humanitarian assistance at USAID, writes in this post in Huffington Post's "The Blog."

5 Mar 2012

Thrombotech receives FDA IND approval for THR-18 Phase IIa clinical trial in stroke victims

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.

5 Mar 2012

IRIN examines pilot project to increase ORS coverage for treatment of child diarrhea

IRIN examines ColaLife -- a pilot project set to start in Zambia in September 2012 that will ship single-dose anti-diarrhea kits (ADKs) in crates of Coca-Cola bottles in an effort to increase the coverage of oral rehydration salts (ORS) for the treatment of diarrhea in children in the developing world.

5 Mar 2012

Nuvilex overcomes fundamental challenges faced in stem cell therapy

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, released information today about the company's cell encapsulation technology and the breakthrough in stem cell research which overcomes specific fundamental challenges faced in stem cell therapy—host rejection and migration of implanted cells away from the target site.

5 Mar 2012

Bill Gates meets MTBVAC TB vaccine researchers in Spain

On 21 February Bill Gates met with Dr. Carlos Martin of the University of Zaragoza and members of his team in Madrid, Spain. The scientists are working on the development of MTBVAC, a new vaccine against tuberculosis (TB). Gates showed great interest in the scientific background of MTBVAC, the most advanced vaccine based on attenuation of Mycobacterium tuberculosis.

5 Mar 2012

Roche selects ICON as technology partner

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Roche as its technology partner for storing and managing medical images collected during the company's clinical research programs.

5 Mar 2012

Small positive personality changes may lead to greater increases in happiness

People's personalities can change considerably over time, say scientists, suggesting that leopards really can change their spots.

5 Mar 2012

Researchers identify mechanism with which cancer cells protect themselves against damage

Although many cancer drugs have already been in use for decades, their mode of action is still unknown. The new research results now challenge a mechanism of action that was previously proposed for a group of drugs and supported with experiments: the Topoisomerase I-inhibitor Camptothecin (Top1 inhibitor for short) and its derivatives used in chemotherapy, Topotecan and Irinotecan.

5 Mar 2012

Access full year 2011 revenues increase 284%

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales.

5 Mar 2012

Concert, Fast Forward partner to advance new approach to treat spasticity and pain in MS

Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).

5 Mar 2012

First Edition: March 5, 2012

Today's headlines include reports setting the scene for the upcoming "Super Tuesday" primary elections and how GOP presidential candidates are pointing to health policy issues as part of the debate.

5 Mar 2012

Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement

Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.

5 Mar 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012

Lixiu, BIEL announce distribution agreement for RecoveryRx devices

BioElectronics Corporation., the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced an agreement with Shanghai Lixiu Medical Devices Co., Ltd. – a subsidiary of Shanghai SuoKang Medical Implants Co., Ltd. -- to sell BIEL's RecoveryRx, chronic wound and surgical devices, throughout the People's Republic of China to licensed medical providers.

5 Mar 2012

Special computer algorithms can help doctors to make rapid diagnoses of known diseases

Just like urine and blood, breath contains traces of the products of metabolism. Such products can also be signs of infection, inflammation or cancer. For their analysis, computational bioinformatics researchers at the Cluster of Excellence "Multimodal Computing and Interaction" at Saarland University developed special computer algorithms that can help doctors to make diagnoses quickly and reliably.

5 Mar 2012

Meda announces positive results from three MP29-02 studies on allergic rhinitis

Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.

5 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

Rep. Camp wants explanation about rising cost of health law

Cost estimates for a key portion of President Barack Obama's health care overhaul law have ballooned by $111 billion from last year's budget, and a senior Republican lawmaker on Friday demanded an explanation.

5 Mar 2012

Bovine collagen can enhance gum healing

Receding gums often result in tooth sensitivity and can lead to decay of the root and persistent inflammation of the gum. New research published in BioMed Central's open access journal Head & Face Medicine demonstrates that a novel method using bovine collagen is able to enhance gum healing. This resulted in thicker margins around the tooth and, in over half the cases, complete coverage of exposed roots.

5 Mar 2012

Study shows how hydra respond to light in the absence of eyes

In the absence of eyes, the fresh water polyp, Hydra magnipapillata, nevertheless reacts to light. They are diurnal, hunting during the day, and are known to move, looping end over end, or contract, in response to light.

4 Mar 2012